A PYMNTS Company

Australia : Nurofen facing $6m headache for misleading consumers

By  |  April 13, 2016

Nurofen ‘should be fined’ $6million for ‘misleading’ shoppers by selling a range of ‘pain-targeted’ tablets which are exactly the same and cost twice as much at the standard range, a watchdog said.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The drug’s maker, Reckitt Benckiser, has lost a court battle against the Australian Competition and Consumer Commission (ACCC) over the ‘pain specific’ products.

    The tablets, which promised to ease tension headaches, back pain, migraine pain and period pain, have been removed from Australian shelves over the past three months.

    All of the products contained the same active ingredient, ibuprofen lysine 342mg, and each had the same effect on pain, the ABC reported.

    Full Content: The Guardian

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.